Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain

Neuropsychopharmacology

Volumn 30, Issue 7, 2005, Pages 1269-1277

  El Mansari, Mostafa ^a,c   Sánchez, Connie ^b   Chouvet, Guy ^a   Renaud, Bernard ^a   Haddjeri, Nasser ^a  

^a UNIVERSITÉ LYON 1   (France)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

5 HT; 5 HT1A receptors; Citalopram; Dorsal raphe; Escitalopram; Hippocampus

Indexed keywords

AUTORECEPTOR; CITALOPRAM; ESCITALOPRAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN; CONTROLLED STUDY; DEPRESSION; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ELECTROPHYSIOLOGY; HIPPOCAMPUS; LONG TERM CARE; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; RAT STRAIN; RECEPTOR DOWN REGULATION; SEROTONINERGIC NERVE CELL; TIME;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; MALE; NEURONS; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 20544472658     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300686     Document Type: Article

References (59)

1. Aghajanian GK (1978). Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. Essays Neurochem Neuropharmacol 3: 1-32.
2. Bel N, Artigas F (1992). Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 229: 101-103.
3. Besson A, Haddjeri N, Blier P, de Montigny C (2000). Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 10: 177-188.
4. Blier P, Bouchard C (1994). Modulation of 5-HT release in the guinea-pig brain following long-term administration of anti-depressant drugs. Br J Pharmacol 113: 485-495.
5. 1A agonist gepirone: electro physiological studies in the rat brain. Synapse 1: 470-480.
6. Blier P, de Montigny C (1983). Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 3: 1270-1278.
7. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220-226.
8. Blier P, de Montigny C (1998). Possible mechanisms underlying the antidepressant and anti-obsessional compulsive disorder responses. Biol Psychiatry 44: 313-323.
9. Blier P, de Montigny C, Azzaro AJ (1986). Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 237: 987-994.
10. Blier P, de Montigny C, Tardiff D (1984). Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat. Psychopharmacology 84: 242-249.
11. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL et al (1997). Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 54: 364-374.
12. (1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 404: 1-12.
13. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63: 331-336.
14. 1A receptors. Br J Pharmacol 142: 469-478.
15. Chaput Y, Blier P, de Montigny C (1986). In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotoninergic terminais. J Neurosci 6: 2796-2801.
16. Chen F, Larsen MB, Neubauer HA, Sinning S, Plenge P, Sánchez C et al (2004). Characterization of two overlapping S-citalopram binding sites on the serotonin transporter. European College of Neuropsychopharmacoly, 17th ECNP Congress, Stockholm, Sweden, October, 2004, P.6.068.
17. Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR et al (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci USA 101: 8186-8191.
18. de Montigny C, Aghajanian GK (1978). Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 22: 1303-1306.
19. de Montigny C, Blier P, Chaput Y (1984). Electrophysiologically- identified serotonin receptors in the rat CNS. Neuropharmacology 23: 1511-1520.
20. 1A receptors: electrophysiological studies in the rat hippocampus and dorsal raphe. J Pharmacol Exp Ther 286: 1239-1247.
21. El Mansari M, Sánchez C, Chouvet G, Haddjeri N (2004). In vivo electrophysiological study of the effects of escitalopram on the rat serotonergic neurotransmission. Coll Int Neuropsychopharmacol 24: 213.
22. Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM et al (2003). Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 64: 243-249.
23. Fish EW, Faccidomo S, Gupta S, Miczek KA (2004). Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. J Pharmacol Exp Ther 308: 474-480.
24. Haddjeri N, Blier P, de Montigny C (1997). Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedeberg's Arch Pharmacol 355: 20-29.
25. 1A receptors. J Neurosci 18: 10150-10156.
26. Haddjeri N, De Montigny C, Curet O, Blier P (1998b). Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. Eur J Pharmacol 343: 179-192.
27. Heninger GR, Charney DS (1987). Mechanisms of action of antidepressant treatments: implications for the ethiology and treatment of depression disorders. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress. Raven Press: New York, pp 535-544.
28. 1A receptor function in brain following agonist or antidepressant administration. Life Sci 72: 1665-1682.
29. Hervas I, Artigas F (1998). Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors. Eur J Pharmacol 358: 9-18.
30. 1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release-I. BMY7378 and prazosin. Neuropharmacology 34: 615-620.
31. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB (2000). Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 14: 177-185.
32. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88: 157-160.
33. Kandel ER, Spencer WA (1961). Electrophysiology of hippocampal neurons. II. After potentials and repetitive firing. J Neurophysiol 24: 243-259.
34. 1A receptors in quiet awake rats: in vivo electrophysiological evidence. Neuropsychopharmacology 24: 141-151.
35. Lepola UM, Wade A, Andersen HF (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 19: 149-155.
36. 1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn Schmiedeberg's Arch Pharmacol 352: 141-148.
37. Maes M, Meltzer HY (1995). The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven press: New York, pp 933-944.
38. Malagié I, Trillat AC, Douvier E, Anmella MC, Dessalies MC, Jacquet C et al (1996). Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 354: 785-790.
39. 1A receptor-mediated regulation of dorsal raphe and hippocampal cell activity. J Neurosci 21: 2178-2185.
40. Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M (2001). Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88: 282-286.
41. Moreno FA, Henninger GR, McGahuey CA, Delgado PL (2000). Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 48: 327-329.
42. Mørk A, Kreilgaard M, Sánchez C (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45: 167-173.
43. 1A agonist and antidepressants. J Pharmacol Exp Ther 260: 16-20.
44. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C et al (1997). Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 94: 5308-5313.
45. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50: 345-350.
46. Piñeyro G, Blier P, Dennis T, de Montigny C (1994). Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 14: 3036-3047.
47. Price LH, Charney DS, Delgado PL (1990). Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drug. J Clin Psychiatry 51: 44-50.
48. Ranck JB (1975). Behavioral correlates and firing repertoires of neurons in the dorsal hippocampal formation and septum of unrestrained rats. In: Isaacson RL, Pribram KH (eds). The Hippocampus. Plenum: New York, pp 207-244.
49. 1A receptors: in vivo micrdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15: 349-360.
50. Rueter LE, de Montigny C, Blier P (1998). Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther 285: 404-412.
51. Sánchez C (2003). R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 464: 155-158.
52. Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen AK et al (2003b). Escitalopram, the S-(+)-enantiomer of citalopram, is selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167: 353-362.
53. Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174: 163-176.
54. Sánchez C, Gruca P, Papp M (2003a). R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14: 465-470.
55. Sánchez C, Kreilgaard M (2004). R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77: 391-398.
56. Schechter LE, Balanos FJ, Gozlan G, Lanfumey L, Haj-Dahmane S, Laporte AM et al (1990). Alterations of central serotonergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther 255: 1335-1347.
57. Stórustovu S, Sánchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M et al (2004). R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142: 172-180.
58. Van Praag HM, Asnis GM, Khan RS (1990). Monoamines and abnormal behaviour: a multiaminergic perspective. Br J Psychiatry 157: 723-734.
59. Wade A, Michael Lemming O, Bang Hedegaard K (2002). Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17: 95-102.